|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:2016
gptkb:FDA
|
|
gptkbp:atccode
|
J05 AP05
|
|
gptkbp:availability
|
widely available
|
|
gptkbp:can_be_combined_with
|
gptkb:sofosbuvir
|
|
gptkbp:casnumber
|
1009110-67-0
|
|
gptkbp:chemical_formula
|
C20 H25 N3 O4 S
|
|
gptkbp:clinical_trial
|
Phase 3
ongoing studies
|
|
gptkbp:clinical_use
|
in combination with sofosbuvir
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:drug_interactions
|
gptkb:St._John's_Wort
gptkb:amiodarone
gptkb:rifampin
|
|
gptkbp:duration
|
12 weeks
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:generic_availability
|
generic versions available
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
velpatasvir
|
|
gptkbp:indication
|
chronic hepatitis C genotype 1-6
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
over 95% cure rate
|
|
gptkbp:lifespan
|
15 hours
|
|
gptkbp:marketed_as
|
gptkb:Epclusa
|
|
gptkbp:mechanism_of_action
|
NS5 A inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
adults
pediatric patients
|
|
gptkbp:pharmaceutical_formulation
|
fixed-dose combination
|
|
gptkbp:pharmacokinetics
|
high bioavailability
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
updated regularly
recommended in treatment guidelines
|
|
gptkbp:research_focus
|
HCV eradication
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
diarrhea
rash
insomnia
elevated liver enzymes
pruritus
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:treatment
|
with ribavirin
|
|
gptkbp:type_of_care
|
important for treatment success
|
|
gptkbp:used_for
|
treatment of hepatitis C
|
|
gptkbp:weight
|
393.55 g/mol
|
|
gptkbp:bfsParent
|
gptkb:virus
|
|
gptkbp:bfsLayer
|
4
|